Business Standard

Monday, December 23, 2024 | 12:56 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

A glimmer of hope but...

...dexamethasone's positive effect on patients with severe Covid-19 infection and no effect on mild ones imply that it will not be used on a large scale

Image
Premium

Devangshu Datta
There may be a new ray of hope for COVID-19 victims. A well-known, easily available steroid seems to reduce mortality in critically ill patients, according to a controlled trial. The steroid, dexamethasone, was given to over 2,100 patients in the RECOVERY trials in the UK, and they were compared to a control group of over 4,300 patients who were not administered the drug.

This drug significantly reduces mortality, although it is not useful for milder cases. In the trial, it cut mortality rates by about one-third in patients on ventilators and reduced mortality about 20 per cent for patients on oxygen
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in